MXPA05000978A - Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas. - Google Patents

Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas.

Info

Publication number
MXPA05000978A
MXPA05000978A MXPA05000978A MXPA05000978A MXPA05000978A MX PA05000978 A MXPA05000978 A MX PA05000978A MX PA05000978 A MXPA05000978 A MX PA05000978A MX PA05000978 A MXPA05000978 A MX PA05000978A MX PA05000978 A MXPA05000978 A MX PA05000978A
Authority
MX
Mexico
Prior art keywords
dysfunction
compound
cocoa powder
pharmaceutical formulations
containing rapid
Prior art date
Application number
MXPA05000978A
Other languages
English (en)
Inventor
Alice C Martino
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of MXPA05000978A publication Critical patent/MXPA05000978A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una formulacion farmaceutica de comienzo rapido que contiene un compuesto para la disfuncion sexual que comprende polvo de cacao, proceso para la manufactura de la composicion y uso de la composicion en terapia para la disfuncion sexual.
MXPA05000978A 2002-08-05 2003-06-18 Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas. MXPA05000978A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202365A SE0202365D0 (sv) 2002-08-05 2002-08-05 New formulation and use thereof
PCT/SE2003/001022 WO2004012702A1 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof

Publications (1)

Publication Number Publication Date
MXPA05000978A true MXPA05000978A (es) 2005-12-12

Family

ID=20288677

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05000978A MXPA05000978A (es) 2002-08-05 2003-06-18 Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas.

Country Status (15)

Country Link
EP (1) EP1539096A1 (es)
JP (1) JP2005539008A (es)
CN (1) CN1674866B (es)
AR (1) AR040797A1 (es)
AU (1) AU2003239038B2 (es)
BR (1) BR0313224A (es)
CA (1) CA2495527C (es)
IL (1) IL166031A0 (es)
MX (1) MXPA05000978A (es)
NZ (1) NZ537520A (es)
RU (1) RU2312665C2 (es)
SE (1) SE0202365D0 (es)
TW (1) TW200418470A (es)
WO (1) WO2004012702A1 (es)
ZA (1) ZA200500051B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
EP3299010B1 (de) 2016-09-21 2022-11-09 LTS Lohmann Therapie-Systeme AG Orale darreichungsform
CA3092458C (en) 2018-03-01 2024-01-30 Lts Lohmann Therapie-Systeme Ag Oral dosage form containing theobromine-free cocoa

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755180A (en) * 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
FR2717387B1 (fr) * 1994-03-17 1996-10-18 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
US6121276A (en) 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
ES2105970B1 (es) * 1995-08-02 1998-07-01 S A L V A T Lab Sa Composicion farmaceutica oral de ciprofloxacino, no acuosa, estable y con caracteristicas organolepticas mejoradas.
CA2178021C (en) * 1996-04-19 1999-09-28 Theodore H. Stanley Tobacco substitute
WO1998030209A1 (en) * 1997-01-06 1998-07-16 Pfizer Pharmaceuticals Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
JP2000095710A (ja) * 1998-09-21 2000-04-04 Taisho Pharmaceut Co Ltd カカオ末を配合した経口用固形製剤
JP2000119198A (ja) * 1998-10-16 2000-04-25 Eisai Co Ltd 苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤
US6060094A (en) * 1998-10-30 2000-05-09 Nestec S.A. Method of reducing fat in fat-based coating for confectionery products
SE9803986D0 (sv) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
US6531114B1 (en) * 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CA2378257A1 (en) 1999-08-10 2001-02-15 William E. Sponsel Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP2001114668A (ja) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd チョコレート剤
CA2394297A1 (en) 1999-12-30 2001-07-12 Tap Holdings, Inc. Oral mucosal dosage forms of apomorphine
CA2417736A1 (en) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
JP2002193839A (ja) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd ココア製剤
AR032556A1 (es) * 2001-02-08 2003-11-12 Pharmacia Corp Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa

Also Published As

Publication number Publication date
SE0202365D0 (sv) 2002-08-05
CN1674866B (zh) 2012-09-26
AU2003239038A1 (en) 2004-02-23
CA2495527C (en) 2008-12-30
CN1674866A (zh) 2005-09-28
WO2004012702A1 (en) 2004-02-12
CA2495527A1 (en) 2004-02-12
AU2003239038B2 (en) 2008-01-03
IL166031A0 (en) 2006-01-15
EP1539096A1 (en) 2005-06-15
TW200418470A (en) 2004-10-01
RU2005102835A (ru) 2005-08-10
JP2005539008A (ja) 2005-12-22
AR040797A1 (es) 2005-04-20
NZ537520A (en) 2006-11-30
ZA200500051B (en) 2006-12-27
RU2312665C2 (ru) 2007-12-20
BR0313224A (pt) 2005-07-05

Similar Documents

Publication Publication Date Title
SE0103211D0 (sv) New formulations and use thereof
TW200510375A (en) New compounds
SI1478339T1 (sl) Farmacevtske formulacije antineoplastičnih sredstev, zlasti temozolomida, postopki za pripravo in uporabo le-teh
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
IL157320A0 (en) Rapid-onset medicament for the treatment of sexual dysfunction
HUP0402063A3 (en) Indole-2-carboxamides process for producing them, pharmaceutical compositions containing them and use thereof
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
HUP0202719A3 (en) Pharmaceutical compositions for the treatment of female sexual dysfunctions
MXPA04003666A (es) Uso de flibanserina para tratamiento de trastornos sexuales.
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
HK1167332A1 (en) Pharmaceutical composition, use thereof and method for making the same
TNSN05046A1 (en) Method of preparing dry powder inhalation compositions
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
TW200503782A (en) New formulations and use thereof
MXPA03010761A (es) Combinaciones farmaceuticas.
SG116507A1 (en) Pharmaceutical dosage form and method of making.
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
WO2003059329A3 (en) Polytartrate composition
SI1404304T1 (sl) Tableta, obsegajoča cetirizin in psevdoefedrin
GR20020100478A (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
MXPA05000978A (es) Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas.
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
MY127675A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration